59 research outputs found
A pilot study of demographic and dopaminergic genetic contributions to weight change in kidney transplant recipients
Kidney transplant recipients often experience a significant amount of weight gain in the first year post-transplantation. While demographic factors such as age, race, and sex have been associated with weight gain in this population, these factors do not explain all of the variability seen. A number of studies have suggested that genetics also plays a critical role in weight changes. Recently, alterations in the activity of the neurotransmitter dopamine have been associated with weight change, and gene expression studies in kidney transplant recipients have supported this association. The purpose of this pilot study is to first examine the feasibility and methodology, and then to examine the associations of age, race, sex, and genotype for 13 SNPs and 3 VNTRs in 9 dopaminergic pathway genes (ANKK1, DRD2, DRD3, DRD4, SLC6A3/DAT1, MAOA, MAOB, COMT, CPE) for associations with percent weight change at 12 months post-transplantation. Seventy kidney transplant recipients had demographic and clinical data collected as a part of a larger observational study. DNA was extracted from repository buffy coat samples taken at the time of transplant, and genotyped using Taqman and PCR based methods. Three SNPs were independently associated with percent weight change: ANKK1 rs1800497 (r = -0.28, p = 0.05), SLC6A3/DAT1 rs6347 (p = 0.046), and CPE rs1946816 (p = 0.028). Stepwise regression modelling confirmed the combined associations of age (p = 0.0021), DRD4 VNTR 4/5 genotype (p = 0.0074), and SLC6A3/DAT1 rs6347 CC genotype (p = 0.0009) and TT genotype (p = 0.0004) with percent weight change in a smaller sample (n = 35) of these kidney transplant recipients that had complete genotyping. These associations indicate that there may be a genetic, and an age component to weight changes post transplantation
Quantitative Mapping of Nanoscale Chemical Dynamics in Sub-Sampled Operando (S)TEM Images using Spatio-Temporal Analytics
Global surveillance of oral tobacco products : total nicotine, unionised nicotine and tobacco-specific N-nitrosamines
OBJECTIVE: Oral tobacco products contain nicotine and
carcinogenic tobacco-specific N-nitrosamines (TSNAs)
that can be absorbed through the oral mucosa. The aim
of this study was to determine typical pH ranges and
concentrations of total nicotine, unionised nicotine (the
most readily absorbed form) and five TSNAs in selected
oral tobacco products distributed globally.
METHODS: A total of 53 oral tobacco products from 5
World Health Organisation (WHO) regions were analysed
for total nicotine and TSNAs, including 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol (NNAL), using gas
chromatography or liquid chromatography with mass
spectrometric detection. Unionised nicotine concentrations
were calculated using product pH and total nicotine
concentrations. Fourier transform infrared spectroscopy
was used to help categorise or characterise some products.
RESULTS: Total nicotine content varied from 0.16 to
34.1 mg/g product, whereas, the calculated unionised
nicotine ranged from 0.05 to 31.0 mg/g product; a 620-fold
range of variation. Products ranged from pH 5.2 to 10.1,
which translates to 0.2% to 99.1% of nicotine being in the
unionised form. Some products have very high pH and
correspondingly high unionised nicotine (eg, gul powder,
chimo´, toombak) and/or high TSNA (eg, toombak, zarda,
khaini) concentrations. The concentrations of TSNAs
spanned five orders of magnitude with concentrations of
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
ranging from 4.5 to 516 000 ng/g product.
CONCLUSIONS: These data have important implications for
risk assessment because they show that very different
exposure risks may be posed through the use of these
chemically diverse oral tobacco products. Because of the
wide chemical variation, oral tobacco products should
not be categorised together when considering the public
health implications of their use.This work was funded by the U.S. Government, Department of Health and
Human Services. This study was also funded internally at the Centers for Disease
Control and Prevention, with funds directly provided by the U.S. federal government.http://tobaccocontrol.bmj.com
Recommended from our members
Parallel computing in information retrieval - An updated review
The progress of parallel computing in Information Retrieval (IR) is reviewed. In particular we stress the importance of the motivation in using parallel computing for Text Retrieval. We analyse parallel IR systems using a classification due to Rasmussen [1] and describe some parallel IR systems. We give a description of the retrieval models used in parallel Information Processing.. We describe areas of research which we believe are needed
Global burden of disease due to smokeless tobacco consumption in adults : analysis of data from 113 countries
BACKGROUND: Smokeless tobacco is consumed in most countries in the world. In view of its widespread use and increasing awareness of the associated risks, there is a need for a detailed assessment of its impact on health. We present the first global estimates of the burden of disease due to consumption of smokeless tobacco by adults. METHODS: The burden attributable to smokeless tobacco use in adults was estimated as a proportion of the disability-adjusted life-years (DALYs) lost and deaths reported in the 2010 Global Burden of Disease study. We used the comparative risk assessment method, which evaluates changes in population health that result from modifying a population's exposure to a risk factor. Population exposure was extrapolated from country-specific prevalence of smokeless tobacco consumption, and changes in population health were estimated using disease-specific risk estimates (relative risks/odds ratios) associated with it. Country-specific prevalence estimates were obtained through systematically searching for all relevant studies. Disease-specific risks were estimated by conducting systematic reviews and meta-analyses based on epidemiological studies. RESULTS: We found adult smokeless tobacco consumption figures for 115 countries and estimated burden of disease figures for 113 of these countries. Our estimates indicate that in 2010, smokeless tobacco use led to 1.7 million DALYs lost and 62,283 deaths due to cancers of mouth, pharynx and oesophagus and, based on data from the benchmark 52 country INTERHEART study, 4.7 million DALYs lost and 204,309 deaths from ischaemic heart disease. Over 85 % of this burden was in South-East Asia. CONCLUSIONS: Smokeless tobacco results in considerable, potentially preventable, global morbidity and mortality from cancer; estimates in relation to ischaemic heart disease need to be interpreted with more caution, but nonetheless suggest that the likely burden of disease is also substantial. The World Health Organization needs to consider incorporating regulation of smokeless tobacco into its Framework Convention for Tobacco Control
Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis
BACKGROUND: Whether overweight or obese end stage renal disease (ESRD) patients are suitable for renal transplantation (RT) is often debated. The objective of this review and meta-analysis was to systematically investigate the outcome of low versus high BMI recipients after RT. METHODS: Comprehensive searches were conducted in MEDLINE OvidSP, Web of Science, Google Scholar, Embase, and CENTRAL (the Cochrane Library 2014, issue 8). We reviewed four major guidelines that are available regarding (potential) RT recipients. The methodology was in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and written based on the PRISMA statement. The quality assessment of studies was performed by using the GRADE tool. A meta-analysis was performed using Review Manager 5.3. Random-effects models were used. RESULTS: After identifying 5,526 studies addressing this topic, 56 studies were included. We extracted data for 37 outcome measures (including data of more than 209,000 RT recipients), of which 26 could be meta-analysed. The following outcome measures demonstrated significant differences in favour of low BMI (<30) recipients: mortality (RR = 1.52), delayed graft function (RR = 1.52), acute rejection (RR = 1.17), 1-, 2-, and 3-year graft survival (RR = 0.97, 0.95, and 0.97), 1-, 2-, and 3-year patient survival (RR = 0.99, 0.99, and 0.99), wound infection and dehiscence (RR = 3.13 and 4.85), NODAT (RR = 2.24), length of hospital stay (2.31 days), operation duration (0.77 hours), hypertension (RR = 1.35), and incisional hernia (RR = 2.72). However, patient survival expressed in hazard ratios was in significant favour of high BMI recipients. Differences in other outcome parameters were not significant. CONCLUSIONS: Several of the pooled outcome measurements show significant benefits for ‘low’ BMI (<30) recipients. Therefore, we postulate that ESRD patients with a BMI >30 preferably should lose weight prior to RT. If this cannot be achieved with common measures, in morbidly obese RT candidates, bariatric surgery could be considered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0340-5) contains supplementary material, which is available to authorized users
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
Malignant pleural mesothelioma (MPM) is an aggressive inflammatory cancer with a poor survival rate. Treatment options are limited at best and drug resistance is common. Thus, there is an urgent need to identify novel therapeutic targets in this disease in order to improve patient outcomes and survival times. MST1R (RON) is a trans-membrane receptor tyrosine kinase (RTK), which is part of the c-MET proto-oncogene family. The only ligand recognized to bind MST1R (RON) is Macrophage Stimulating 1 (MST1), also known as Macrophage Stimulating Protein (MSP) or Hepatocyte Growth Factor-Like Protein (HGFL). In this study, we demonstrate that the MST1-MST1R (RON) signaling axis is active in MPM. Targeting this pathway with a small molecule inhibitor, LCRF-0004, resulted in decreased proliferation with a concomitant increase in apoptosis. Cell cycle progression was also affected. Recombinant MST1 treatment was unable to overcome the effect of LCRF-0004 in terms of either proliferation or apoptosis. Subsequently, the effect of an additional small molecular inhibitor, BMS-777607 (which targets MST1R (RON), MET, Tyro3, and Axl) also resulted in a decreased proliferative capacity of MPM cells. In a cohort of MPM patient samples, high positivity for total MST1R by IHC was an independent predictor of favorable prognosis. Additionally, elevated expression levels of MST1 also correlated with better survival. This study also determined the efficacy of LCRF-0004 and BMS-777607 in xenograft MPM models. Both LCRF-0004 and BMS-777607 demonstrated significant anti-tumor efficacy in vitro, however BMS-777607 was far superior to LCRF-0004. The in vivo and in vitro data generated by this study indicates that a multi-TKI, targeting the MST1R/MET/TAM signaling pathways, may provide a more effective therapeutic strategy for the treatment of MPM as opposed to targeting MST1R alone
A hierarchical method to automatically encode Chinese diagnoses through semantic similarity estimation
- …